KSD-101 for advanced nasopharyngeal cancer after standard treatment failed
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a new treatment (KSD-101) for nasopharyngeal cancer that has not responded to standard therapies. It aims to see if this treatment can help when other options have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have nasopharyngeal cancer that is linked to the Epstein-Barr virus (EBV), confirmed by a biopsy.
- You must have tried at least 3 different treatments, and the cancer has either come back in the same area or spread to other parts.
- You need to have at least one tumor that can be measured on a scan.
- Your overall health should be good (you're able to do light activities), and your blood and organ function tests must meet certain levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (BL-B01D1) given alone or with another drug that helps the immune system fight cancer (called a PD-1 inhibitor). It is for people with newly diagnosed, locally advanced nasopharyngeal cancer. The goal is to see if this combination can shrink or control the cancer better.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests a new drug, JS207, which targets two proteins (PD-1 and VEGF) that help cancer grow. It's for people with nasopharyngeal cancer that has not spread too much, and who have not had certain prior treatments.
This trial tests a new cell therapy called KSD-101 for nasopharyngeal cancer that has not responded to standard treatments. The therapy is injected into your lymph nodes and works by boosting your immune system to fight the cancer.
This trial tests a new study treatment called KSD-101 for blood cancers linked to the Epstein-Barr virus (EBV) that have come back or not responded to other treatments. The goal is to see if it is safe and effective for people with these types of cancer.
This study tests a new drug, SNB-101, for people with small cell lung cancer that has spread and has worsened after standard therapy. It aims to find out if SNB-101 can help control the cancer and what side effects it may cause.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.